Efavirenz as a potential drug for the treatment of triple-negative breast cancers.

P-T ChiouS OhmsP G BoardJ E DahlstromD RangasamyMarco G Casarotto

Published in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2020)

In summary, we propose Efavirenz is a potential anti-TNBC drug and that its mode of action can be linked to the fatty acid metabolism pathway.

Keyphrases

fatty acid
hiv infected
antiretroviral therapy
hiv infected patients
drug induced
emergency department
young adults
climate change
replacement therapy